

A photograph of a family in a clinical setting. A doctor in a white lab coat is on the left, facing a woman and a young girl. The woman is smiling and has her hand raised, and the girl is also smiling and has her hand raised towards the doctor. The background shows a bookshelf with books and a small potted plant.

Genetic Signatures

Investor presentation

August 2020



Disclaimer

This presentation has been prepared by Genetic Signatures Limited (“GSS”). The information contained in this presentation is for information purposes only and has been prepared for use in conjunction with a verbal presentation and should be read in that context. This presentation is proprietary to GSS. It may not be reproduced, disseminated, quoted or referred to, in whole or in part, without the express consent of GSS.

The information contained in this presentation is not investment or financial product advice and is not intended to be used as the basis for making an investment decision. Please note that, in providing this presentation, GSS has not considered the objectives, financial position or needs of any particular recipient. GSS strongly suggests that investors consult a financial advisor prior to making an investment decision.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of GSS, its related bodies corporate, shareholders or respective directors, officers, employees, agents or advisors, nor any other person accepts any liability, including, without limitation, any liability arising out of fault or negligence for any loss arising from the use of information contained in this presentation.

This presentation includes “forward looking statements” within the meaning of securities laws of applicable jurisdictions. Forward looking statements can generally be identified by the use of the words “anticipate”, “believe”, “expect”, “project”, “forecast”, “estimate”, “likely”, “intend”, “should”, “could”, “may”, “target”, “plan” “guidance” and other similar expressions. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of GSS and its officers, employees, agents or associates, that may cause actual results to differ materially from those expressed or implied in such statement. Actual results, performance or achievements may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based. Readers are cautioned not to place undue reliance on forward looking statements and GSS assumes no obligation to update such information.

This presentation is not, and does not constitute, an offer to sell or the solicitation, invitation or recommendation to purchase, any securities and neither this presentation nor anything contained in it forms the basis of any contract or commitment. Without limiting this, this presentation does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. The securities of GSS have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (Securities Act) or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States except in compliance with the registration requirements of the Securities Act and any other applicable securities laws or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws.

Investment highlights



Trusted and proven technology

- 100% customer retention since 2016 and the accuracy of the technology has been clinically validated¹



Competitive advantage

- Underpinned by novel 3base™ technology providing increased throughput capacity, reduced time to results and significant cost savings



Significant opportunity created by COVID-19

- Leverage internal capabilities to develop a new test for SARS-CoV-2 and scale up manufacturing capacity to meet the significant COVID-19 related increase in customer demand



Global expansion strategy

- Increasing international recognition through the SARS-CoV-2 launch creates new avenues to expand customer base



Attractive and scalable

- Business model with favourable unit economics expected to underpin growth through FY21 and beyond




Multiple upcoming catalysts in FY21

- Multiple global growth opportunities to be pursued in tandem, each representing potential upside

1. <https://geneticsignatures.com/au/publications/>

Genetic Signatures has had an outstanding year against the backdrop of the COVID-19 pandemic, reflected by positive share price performance




Significant revenue growth and continued to achieve strong year-on-year revenue growth and a milestone quarter in 4Q FY2020



Revenue (A\$m)

59% core revenue CAGR (FY17-20)



Exceptional year for Genetic Signatures

- ✓ Revenue for **FY20 of \$11.3m**, a **+131%** on pcp
- ✓ Record quarterly revenue in 4Q FY20 of **\$7.0m**, a **+351%** on pcp, includes instrument sales of **~\$1.0m**
- ✓ Rapid development of **SARS-CoV-2 kit** driving significant domestic and international sales
- ✓ Sales to European customers represented **~10% of total sales for the year and strong demand** from existing domestic customers
- ✓ **Increased manufacturing capacity** within existing infrastructure to cater for the increased demand
- ✓ Significantly **increased inventory holdings** to meet growing demand
- ✓ Considerable **investment in instrumentation**
- ✓ Strong cash balance as at 30 June 2020 of **\$31.2m**

Financial performance

A\$000	Year ending 30 June 2020	Year ending 30 June 2019
Sales revenue	11,263	4,866
Other income	2,910	2,327
Total revenue	14,173	7,193
Cost of goods sold	(4,305)	(1,686)
Employee benefits expense	(6,671)	(4,933)
Other expense items	(4,367)	(3,594)
EBITDA	(1,170)	(3,020)
Depreciation and amortization	(883)	(471)
EBIT	(2,053)	(3,491)
Finance costs	(33)	(1)
(Loss) / profit before tax expenses	(2,086)	(3,492)
Income tax benefit / (expense)	-	-
Net (loss) / profit after tax	(2,086)	(3,492)
Earnings per share (cents)	(1.64)	(3.36)

- Revenue of \$11.3m ,**+131% on pcp** driven by **demand for SARS-CoV-2 test**
 - Other revenue includes R&D tax rebate of \$2.6m
- Expense up ~35% relative to pcp with:
 - **Additional personnel** added to the teams in Europe, USA and locally across all functions
 - Scientific consumables increased 50% on pcp, reflecting the **work on SARS-CoV-2**
 - R&D projects and initial clinical trial activity for the **FDA Enteric Protozoan submission**
- Net loss of \$2.1m in FY20, a **+\$1.4m improvement** over FY19
 - **2H FY20 was a maiden profit** of \$0.3m, showing the impact of higher sales

A strong cash balance of \$31m positions the Company well to drive future growth

Trusted and proven technology – the *EasyScreen*TM products are built on **3base**TM technology



Our Products

Transforming **molecular diagnostics** via streamlined sample processing methods linked to highly **multiplexed real-time PCR screening assays**.

Our automated **sample preparation** method is suitable for **bacterial, protozoan and viral (DNA & RNA)** targets.


The *EasyScreen*TM Detection assays **simultaneously detect a larger number of pathogen targets** in a shorter time than conventional methods.



GS-mini



GS1-HT



GS-1000

Broad suite of EasyScreen™ Detection Kits targeting significant addressable markets



EasyScreen™ Products



**Global market size of
~A\$10bn per annum**

Sources: World Market for Molecular Diagnostics, 5th. Edition (Infectious Disease, Oncology, Blood Screening, Pre-Natal and Other Areas) Kalorama Information, Published: 1/9/2013 & company estimates; Molecular Diagnostics Markets in the COVID-19 Era (Markets for Molecular COVID-19 IVD Tests, Respiratory Tests, Blood Screening, Cancer Markers and Other IVD Tests), Published: 9/7/2020

Rapid development of SARS-CoV-2 kit and scaled up manufacturing capacity to meet a significant increase in customer demand



Strongly positioned to test for SARS-CoV-2



The SARS-CoV-2 Test can be used **alone or in conjunction** with the broader *EasyScreen™* Respiratory Kit



3base™ provides **resistance to genetic drift** or mutations of pathogens over time allowing **preservation of clinical specificity**



High throughput allows **testing** of up to 1,500 samples in a 24-hour period in batches of 94 to 188 samples per run

EasyScreen™ SARS-CoV-2 Detection Kit update



CE-IVD and TGA received – kits available for sale in Europe and Australia



FDA EUA¹ application submitted and awaiting clearance. Can now sell to select customers in the US under a Section IVc exemption²



Testing underway in Australia and EMEA with customers using the kits for routine testing



Driving global sales - international sales team and distributors in place in key regions



Expanded sales force - new appointments made to promote kits globally

Genetic Signatures can proudly claim that none of its customers has been without product to undertake testing to date

1. Emergency Use Authorisation
2. The FDA is permitting manufacturers that have or will submit an EUA for a SARS-CoV-2 test to supply their test prior to receiving the EUA. The FDA describes this marketing route in Section IV.C. of their Policy for Coronavirus Disease-2019 (<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-coronavirus-disease-2019-tests-during-public-health-emergency-revised>)

Competitive advantage - Genetic Signatures' 3base™ technology creates potential benefits for multiple key stakeholders



Patients

- ✓ **qPCR¹ detection methodology** used, the gold standard for infectious disease diagnosis
- ✓ **Rapid time to results**, with results processed from 4 hours, for up to 188 specimens
- ✓ Screening for **more targets** per patient specimen **increases accuracy of diagnosis**
- ✓ **Accelerates treatment path** and **reduces mortality and morbidity**



Laboratories

- ✓ **Clear competitive advantage** for target customer base of **high throughput labs**
- ✓ **Reduces customer costs** through accurate detection and minimising hands on time
- ✓ **Reduced complexity** in molecular testing



Governments

- ✓ **Reduced hospital stays** with **broad and accurate** detection of infectious disease
- ✓ Fast turnaround and accurate detection **reduces the spread of disease**
- ✓ Testing for **more targets per specimen** **reduces repeat doctor visits**
- ✓ **Reduces overuse and misuse of antibiotics**

1. Real-time polymerase chain reaction (real-time PCR), also known as quantitative polymerase chain reaction (qPCR)

Growth underpinned by scalable revenue model and attractive unit economics supported by expanding pipeline of new customers / tenders



Attractive revenue model



High throughput with predictable orders

Target **high throughput** pathology groups, hospitals or government run programs

Secure long-standing customer relationships with **predictable volumes**

Customers typically have **regular ordering patterns**



Sticky annuity revenue

“**Printer & cartridge**” model - tests become **embedded in workflow**

Customers may **adopt new tests** once workflow established

100% customer retention since 2016




Attractive return on investment

Potential to **fund new customer installations**

Speeds up customer acquisition, particularly offshore

Consumable revenue model - customers pay per test

Global strategy for commercialisation - COVID-19 pandemic has created an opportunity to accelerate international expansion



1 North America: Accelerate market entry

- FDA EUA request submitted for SARS-CoV-2 kit, awaiting final clearance
- Can now sell to select customers in the US under a Section IVc exemption¹ until FDA EUA is received
- New sales team appointed with strong pedigree in the industry
- Initial clinical work has now commenced for FDA clearance of the *EasyScreen*[™] Enteric Protozoan Detection Kit

2 EMEA: Focused on increasing customer acquisitions

- CE-IVD received for SARS-CoV-2 kit and product launched
- New customers established, including 3 new distributors
- 4 test kits registered for sale including the SARS-CoV-2 test
- 2 additional products approaching CE-IVD registration, with application lodged for STI / Genital Pathogen kit in 4Q FY20

3 APAC: Continued sales expansion

- TGA registration and launch of *EasyScreen*[™] SARS-CoV-2 kit
- New customers adopt *EasyScreen*[™] SARS-CoV-2 test
- Production capacity increased to meet current demand and further expansion underway
- Application lodged with TGA for STI / Genital kit to be included on ARTG

1. The FDA is permitting manufacturers that have or will submit an EUA for a SARS-CoV-2 test to supply their test prior to receiving the EUA. The FDA describes this marketing route in Section IV.C. of their Policy for Coronavirus Disease-2019 (<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-coronavirus-disease-2019-tests-during-public-health-emergency-revised>)

On track to achieve multiple commercial milestones in FY21 that could accelerate revenue growth



Near term opportunities for SARS-CoV-2 commercialisation

- ✓ **CE-IVD received** allowing marketing of the kit in Europe with **orders received**
- ✓ TGA registration received allowing marketing of the kit in Australia with **orders received**
- FDA EUA has been submitted for SARS-CoV-2 kit, **awaiting final clearance**
- **Targeting first US customer contract** for SARS-CoV-2 product¹

Launching EasyScreen™ products in new markets

- TGA / CE-IVD submission for the STI / Genital kit filed in 4Q FY20 **with clearance anticipated in the coming months**
- Well positioned to progress regulatory applications when COVID-19 restrictions lift:
 - Clinical trials initiated for the FDA submission for the Enteric Protozoan kit
 - TGA / CE-IVD submissions for the Flavivirus / Alphavirus kit

Leverage growing international exposure to drive new contract wins

- ✓ COVID-19 pandemic has given Genetic Signatures an opportunity to **demonstrate its technology** and broader syndromic testing platform to a greater range of customers
- Interest in the SARS-CoV-2 products likely to drive interest in broader range of *EasyScreen™* multiplex kits and facilitate **new contracts in US and Europe**

1. The FDA is permitting manufacturers that have or will submit an EUA for a SARS-CoV-2 test to supply their test prior to receiving the EUA. The FDA describes this marketing route in Section IV.C. of their Policy for Coronavirus Disease-2019 (<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-coronavirus-disease-2019-tests-during-public-health-emergency-revised>)

Appendices







**Genetic
Signatures**

Transforming
Molecular
Diagnostics

A global leader in the supply of molecular diagnostic solutions

A specialist molecular diagnostics company

-  Focused on becoming a global leader in the supply of molecular diagnostic solutions
-  Developing and commercialising its proprietary platform technology, **3base™**
-  Implementing its commercial strategy through teams in Australia, Europe and North America
-  Scalable business which has achieved strong core revenue growth



Financial information

Share price (26-Aug-20)	A\$2.30
Shares on issue	142.6m ¹
Market capitalisation	A\$328.0m
Cash (30-Jun-20)	A\$31.2m
Debt (30-Jun-20)	Nil
Enterprise value	A\$296.8m

Top shareholders %

Asia Union (Chris Abbott private investment)	26.7%
Karst Peak (HK-based investment manager)	11.2%
Perennial Value Management	9.4%
Fidelity International	7.7%
Directors, management & advisors	3.5%


1: Excludes 3.28m unquoted options (various expiration dates and prices)

Novel proprietary technology - proprietary 3base™ platform technology underpins the EasyScreen™ product range



Our proprietary 3base™ solution...

- 1 **3base™** platform technology converts original 4-base microbial genome to 3-base
- 2 Conversion occurs during standard procedures with no additional steps for the technician
- 3 **3base™** MDx can identify a wider array of pathogens and provide greater testing accuracy by reducing complexity in a multiplex environment



1,048,576
combinations for a 10 digit number with 4-base

↓

59,049
combinations for a 10 digit number with 3-base

...improves workflow and increases throughput



EasyScreen™ kits are compatible with most existing automated nucleic acid extraction and real-time PCR instruments and **streamline the preparation process**



High throughput labs can achieve **further workflow automation** with compatible hardware. Creates **workflow efficiencies and reduce costs**



Currently offering over 100 pathogen targets across enteric, respiratory, anti-microbial resistance, sexual health and tropical diseases

Board of Directors with proven track records of commercialisation success across key geographic regions



Nick Samaras

**Non-Executive
Chairman**

- Significant experience in leading international sales expansions of biotech companies
- Former Managing Director of **Applied Biosystems** (acquired by ThermoFisher, US\$76.8bn market cap)
- Held senior roles with **Perkin Elmer** and **AMRAD Corporation** (now part of CSL)



John Melki

**Managing Director &
Chief Executive Office**

- **Led global commercialisation efforts of GSS since 2011** and the product development team since 2003
- Successfully **commercialised seven products globally**
- Authored 20 peer-reviewed articles and listed as an inventor on eight patent applications



Michael Aicher

Executive Director

- Founder and former CEO of **National Genetics Institute** (subsidiary of LabCorp, US\$15.3bn market cap)
- Led Lab-Corp's Esoteric Business Units which generated over US\$1b revenue p.a.
- Former executive roles at **Central Diagnostics Laboratory**
- Recipient of Ernst & Young "**Entrepreneur of the Year**" award for emerging technologies



Tony Radford AO

Non-Executive Director

- Former Co-Founder and CEO of **Cellestis** (ASX:CST, acquired by QIAGEN for c.A\$350m in 2011)
- Former member of CSIRO team that invented QuantIFERON
- Former Head of Development at **AMRAD** (later acquired by CSL)

International management team of highly skilled researchers and executives bring a broad array of experience and knowledge



Dr. Doug Millar
Chief Scientific Officer

- One of the pioneers of the bisulphite genomic sequencing protocol with a PhD in Molecular Genetics
- Key inventor on over **30 patents** or pending patent applications held by the company
- Authored **23 peer reviewed scientific papers** and presented at 20+ international conferences



Peter Manley
Chief Financial Officer
& Company Secretary

- Led the recent Genetic Signatures capital raise, successfully securing \$37.5m
- Served as CFO and Company Secretary for **AtCor Medical** (now Cardiox) and **Sirtex Medical**
- Senior financial positions including 8 years with **Dow Chemical** and 4 years at **Goodman Fielder**



Jackson Jones
Director of Global
Sales & Marketing

- **20+ years experience** in clinical diagnostics, blood banking, and life sciences sector
- Joined Genetic Signatures in 2017 and brings significant commercial experience from working with **several large US multinationals** and roles across **Australasia, Europe, and North America**



Derek Joesting
Director of Sales -
North America

- **20+ years of medical sales experience** with broad sector experience
- Previously held **leadership roles in molecular diagnostics** and pathology sales in North America
- Holds a Bachelor of Science degree in Biology from Syracuse University



John Buckels
Director of Sales &
Support - Europe

- **20+ years' experience** in molecular biology and sales across the EMEA
- Former **Senior Director and Head of Infectious Diseases sales at QIAGEN** and 13 years experience in sales and marketing



Neralie Coulston
Regulatory Affairs
Manager

- Supported Genetic Signatures since 2002 and **brings significant experiences in Quality System and Regulatory Affairs**
- Former roles at the **CSIRO and UNSW** on both **therapeutic development and research** programs

Contact us

Dr John Melki

Genetic Signatures

Chief Executive Officer

P: +61 (0)2 9870 7580

E: john.melki@geneticsignatures.com

Peter Manley

Genetic Signatures

Chief Financial Officer

P: +61 (0)2 9870 7580

E: peter.manley@geneticsignatures.com

Genetic Signatures

Transforming
Molecular
Diagnostics

Visit us

www.geneticsignatures.com

Follow us on social media

